Merck & Co.
As a leader in biopharmaceuticals, we focus on scientific innovation to deliver medicines and vaccines that may help millions of people around the world.
We’re a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies and animal health products. We’re focused on discovering new solutions for today and the future.
We aspire to be the premier research-intensive biopharmaceutical company. We’re at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
Explore Careers In
Our Therapeutic Areas:
We hold ourselves to the highest standards of ethics and integrity.
We’re driven by a desire to improve life
Our values represent the core of our character and guide every decision and action we take.
Patients first
Respect for people
Ethics and integrity
Innovation and scientific excellence
Don’t just join a company … find a sense of belonging! Our Employee Business Resource Groups (EBRGs) are voluntary, employee-led groups that aim to foster a diverse, inclusive work environment by supporting career development while providing culturally relevant insights that drive success. These groups and the people in them will provide a warm welcome to you.
Get to know us personally through employee spotlights, blogs and our podcast! Follow us on careers social for interview tips, resume tips, DEI, divisional information and more!
X | Facebook | Instagram | YouTube | Careers Blog | Career On Purpose Podcast
Blog Post
Sherif Chalifa, Business Analyst for Quality Systems
Sherif Chalifa, Business Analyst for Quality Systems
As I reflect on my time since joining Merck earlier this year, I am thrilled to say that it has been an excellent experience thus far.
Our Business
Our Business
Our Business
Make a change
Make a change
How we hire
How we hire
A decade of oncology advancements
A decade of oncology advancements
NEWS
BMS and Opdivo’s blockbuster checkpoint inhibitor picked up a new regulatory win after the FDA approved the cancer drug in combination with platinum-doublet chemotherapy.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
A new market research report by InsightAce Analytic projects the immuno-oncology or cancer immunotherapy market will hit $34.69 billion by 2030.
Dr. Julie L. Gerberding, Merck’s chief patient officer and executive vice president of population health and sustainability, is retiring from Merck after 12 years.
Belgium-based Celyad Oncology voluntarily paused a clinical trial with Merck after two deaths. Getting CAR T therapies to work in solid tumors has proven to be a difficult challenge.
Throughout history, many different countries have had their biopharma supply chains changed – sometimes profitably, sometimes detrimentally – by war.
Celyad announced that it is voluntarily pausing a clinical trial it’s conducting with Merck after reports of two patient deaths.
The arrangement provides the opportunity for LJI faculty and postdocs to make a more immediate impact on drug development while offering a different perspective to KKNA.
BioSpace compared the 43 healthcare and life science companies on Newsweek’s list of America’s Most Responsible Companies for 2022 with that of our own 2022 Best Places to Work.
JOBS
IN THE PRESS